ciprofibrate has been researched along with Apolipoprotein B-100, Familial Defective in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Simvastatin was associated with statistically significantly greater (p < or = 0." | 2.68 | Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. ( Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W, 1995) |
| " Safety was assessed from reports of adverse events and by measuring haematological and biochemical parameters." | 2.68 | Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia. ( Betteridge, DJ; O'Bryan-Tear, CG, 1996) |
| "Ciprofibrate has the benefit of a long half-life and may also be administered in the form of a single daily dose to patients suffering from major type II hyperlipoproteinaemia." | 2.66 | Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. ( Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J, 1985) |
| "Ciprofibrate was convenient to take and was without subjective side effects." | 1.26 | Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. ( Olsson, AG; Orö, L, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guerin, M | 1 |
| Le Goff, W | 1 |
| Frisdal, E | 1 |
| Schneider, S | 1 |
| Milosavljevic, D | 1 |
| Bruckert, E | 2 |
| Chapman, MJ | 1 |
| Illingworth, DR | 1 |
| Olsen, GD | 1 |
| Cook, SF | 1 |
| Sexton, GJ | 1 |
| Wendel, HA | 1 |
| Connor, WE | 1 |
| Olsson, AG | 1 |
| Orö, L | 1 |
| De Gennes, JL | 1 |
| Malbecq, W | 1 |
| Baigts, F | 1 |
| Betteridge, DJ | 1 |
| O'Bryan-Tear, CG | 1 |
| Kockx, M | 1 |
| de Maat, MP | 1 |
| Knipscheer, HC | 1 |
| Kastelein, JJ | 1 |
| Kluft, C | 1 |
| Princen, HM | 1 |
| Kooistra, T | 1 |
| Okopien, B | 1 |
| Cwalina, L | 1 |
| Lebek, M | 1 |
| Kowalski, J | 1 |
| Zielinski, M | 1 |
| Wisniewska-Wanat, M | 1 |
| Kalina, Z | 1 |
| Herman, ZS | 1 |
| Hunninghake, DB | 1 |
| Peters, JR | 1 |
| Palmer, RH | 1 |
| Jacotot, B | 1 |
| Beaumont, JL | 1 |
| Beaumont, V | 1 |
| Buxtorf, JC | 1 |
| Edouard, L | 1 |
| Doucet, F | 1 |
| Carcone, B | 1 |
| Rouffy, J | 1 |
| Chanu, B | 1 |
| Bakir, R | 1 |
| Djian, F | 1 |
| Goy-Loeper, J | 1 |
2 reviews available for ciprofibrate and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfib | 1987 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Feno | 1987 |
9 trials available for ciprofibrate and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
Topics: Adult; Animals; Apolipoprotein A-I; Apolipoproteins B; Arteriosclerosis; Cholesterol; Cholesterol Es | 2003 |
Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.
Topics: Adult; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fibric Aci | 1982 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Fema | 1995 |
Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Delayed-A | 1996 |
Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
Topics: Adult; Aged; Cholesterol; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Gem | 1997 |
Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Fibrin | 2001 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Feno | 1987 |
Effects of several lipid-lowering drugs on skin total and esterified cholesterol.
Topics: Cholesterol Esters; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hyp | 1986 |
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Topics: Adult; Apolipoproteins A; Apolipoproteins B; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Fe | 1985 |
1 other study available for ciprofibrate and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Body Weight; Cholesterol; Ch | 1982 |